Pathological significance and regulatory mechanism of lymphotoxin β receptor overexpression in T cells of patients with systemic lupus erythematosus

Abstract

Systemic lupus erythematosus (SLE) is a typical autoimmune disease. Lymphotoxin β receptor (LTβR) signaling plays an important role in autoimmune inflammations. LTβR-Ig fusion protein, LTβR blocking agent, has been used to treat SLE, while its mechanism remains to be fully elucidated. In this study, to investigate the expression of LTβR in the T cells of SLE patients and its roles in the pathogenesis of SLE, we isolated the peripheral blood T cells of SLE patients and normal controls to detect expression of LTβR by flow cytometry and RNA assay. T cells were also stimulated with LIGHT, a ligand of LTβR, and then detected for their LTβR expressions and apoptosis by flow cytometry. Also, their expressions of inflammatory factors and receptors were determined by RNA assay. The results showed that LTβR positive cells were 22.75%±6.98% in CD3⁺ cells of SLE patients, while there were almost no LTβR positive cells in CD3⁺ cells of normal persons. Moreover, LTβR expression was remarkably higher in CD3, CD4 and CD8 positive T cells of active SLE patients than non/low active patients (all P<0.05), and positively correlated with increased Ig level, decreased complement level and renal damage. Moreover, the stimulation of SLE T cells with LIGHT promoted higher expression of LTβR, IL-23R and IL-17A, and apoptosis of T cells. In conclusion, we demonstrated a high expression of LTβR in the T cells of SLE patients which may be associated with pathogenesis of SLE.

Keywords

lupus erythematosus / systemic (SLE) / lymphotoxin β receptor (LTβR) / interleukin-17 (IL-17) / interleukin-23 receptor (IL-23R)

References

[1] Ware CF. Network communications: lymphotoxins, LIGHT, and TNF[J]. Annu Rev Immunol, 2005, 23: 787–819

[2] Gommerman JL. A role for the lymphotoxin/LIGHT pathway in T-cell mediated autoimmunity and infectious disease[J]. Clin Appl Immunol Rev, 2004, 4: 367–393.

[3] Anand S, Wang P, Yoshimura K, Essential role of TNF family molecule LIGHT as a cytokine in the pathogenesis of hepatitis[J]. J Clin Invest, 2006, 116(4): 1045–1051

[4] Madge LA, Kluger MS, Orange JS, Lymphotoxin-alpha 1 beta 2 and LIGHT induce classical and noncanonical NF-kappa B-dependent proinflammatory gene expression in vascular endothelial cells[J]. J Immunol, 2008, 180(5): 3467–3477

[5] Takatori H, Kanno Y, Chen Z, New complexities in helper T cell fate determination and the implications for autoimmune diseases[J]. Mod Rheumatol, 2008, 18(6): 533–541

[6] Chiang EY, Kolumam GA, Yu X, Targeted depletion of lymphotoxin-alpha-expressing TH1 and TH17 cells inhibits autoimmune disease[J]. Nat Med, 2009, 15(7): 766–773

[7] Fava RA, Notidis E, Hunt J, A role for the lymphotoxin/LIGHT axis in the pathogenesis of murine collagen-induced arthritis[J]. J Immunol, 2003, 171(1): 115–126

[8] Plant SR, Iocca HA, Wang Y, Lymphotoxin beta receptor (Lt betaR): dual roles in demyelination and remyelination and successful therapeutic intervention using Lt betaR-Ig protein[J]. J Neurosci, 2007, 27(28): 7429–7437

[9] An MM, Fan KX, Cao YB, Lymphtoxin beta receptor-Ig protects from T-cell-mediated liver injury in mice through blocking LIGHT/HVEM signaling[J]. Biol Pharm Bull, 2006, 29(10): 2025–2030

[10] Bagavant H, Deshmukh US, Wang H, Role for nephritogenic T cells in lupus glomerulonephritis: progression to renal failure is accompanied by T cell activation and expansion in regional lymph nodes[J]. J Immunol, 2006, 177(11): 8258–8265

[11] Crispín JC, Oukka M, Bayliss G, Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys[J]. J Immunol, 2008, 181(12): 8761–8766

[12] Korn T, Bettelli E, Oukka M, IL-17 and Th17 Cells[J]. Annu Rev Immunol, 2009, 27: 485–517

[13] Bettelli E, Korn T, Kuchroo VK. Th17: the third member of the effector T cell trilogy[J]. Curr Opin Immunol, 2007, 19(6): 652–657

[14] Wong CK, Lit LC, Tam LS, Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity[J]. Clin Immunol, 2008, 127(3): 385–393

[15] Iwakura Y, Ishigame H. The IL-23/IL-17 axis in inflammation[J]. J Clin Invest, 2006, 116(5): 1218–1222

[16] Zhang Z, Kyttaris VC, Tsokos GC. The role of IL-23/IL-17 axis in lupus nephritis[J]. J Immunol, 2009, 183(5): 3160–3169

[17] Gaffen SL, Jain R, Garg AV, The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing[J]. Nat Rev Immunol, 2014, 14(9): 585–600

[18] Puwipirom H, Hirankarn N, Sodsai P, Increased interleukin-23 receptor(⁺⁾ T cells in peripheral blood mononuclear cells of patients with systemic lupus erythematosus[J]. Arthritis Res Ther, 2010, 12(6): R215

[19] Wang H, Xu J, Ji X, The abnormal apoptosis of T cell subsets and possible involvement of IL-10 in systemic lupus erythematosus[J]. Cell Immunol, 2005, 235(2): 117–121

[20] Yang X, Sun B, Wang H, Increased serum IL-10 in lupus patients promotes apoptosis of T cell subsets via the caspase 8 pathway initiated by Fas signaling[J]. J Biomed Res, 2015, 29(3): 232–240

[21] Mellor-Pita S, Citores MJ, Castejon R, Monocytes and T lymphocytes contribute to a predominance of interleukin 6 and interleukin 10 in systemic lupus erythematosus[J]. Cytometry B Clin Cytom, 2009, 76(4): 261–270

[22] Lee Y, Awasthi A, Yosef N, Induction and molecular signature of pathogenic TH17 cells[J]. Nat Immunol, 2012, 13(10): 991–999

[23] Valencia X, Yarboro C, Illei G, Deficient CD4⁺CD25^high T regulatory cell function in patients with active systemic lupus erythematosus[J]. J Immunol, 2007, 178(4): 2579–2588

[24] Zheng SG, Gray JD, Ohtsuka K, Generation ex vivo of TGF-beta-producing regulatory T cells from CD4⁺CD25⁻ precursors[J]. J Immunol, 2002, 169(8): 4183–4189

[25] Huber S, Stahl FR, Schrader J, Activin a promotes the TGF-beta-induced conversion of CD4⁺CD25⁻ T cells into Foxp3⁺ induced regulatory T cells[J]. J Immunol, 2009, 182(8): 4633–4640

RIGHTS & PERMISSIONS

2017 2017 by the Journal of Biomedical Research.